Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.

Abstract

This article presents the results of group discussion among experts from SIE, SIES and GITMO societies aimed at highlighting unmet challenges in the management of Ph-neg myeloproliferative neoplasms (MPNs). The issues analyzed were: diagnosis of prefibrotic myelofibrosis; diagnosis of Ph-neg MPNs in the setting of splanchnic vein thrombosis (SVT); management of low-risk PV and low-risk ET patients with JAK2V617F mutation; molecular biomarkers in the prognostic evaluation of myelofibrosis (MF); ruxolitinib therapy in low-risk MF; therapy in patients with SVT-associated Ph-neg MPN; indications of splenectomy in MF. For each of these issues, proposals for advancement in clinical research were addressed.

• Authors: Giovanni Barosi, Alessandro M Vannucchi, Valerio De Stefano, Fabrizio Pane, Francesco Passamonti, Alessandro Rambaldi, Giuseppe Saglio, Tiziano Barbui, Sante Tura
• Journal: Leukemia research (Leuk Res) Vol. 38 Issue 2 Pg. 155-60 (Feb 2014) ISSN: 1873-5835 [Electronic] England
• PMID: 24378116 (Publication Type: Consensus Development Conference, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• JAK2 protein, human
• Janus Kinase 2

Topics

• Aged
• Aged, 80 and over
• Amino Acid Substitution
• Consensus
• Expert Testimony
• Female
• Health Services Accessibility
• Health Services Needs and Demand
• Humans
• Janus Kinase 2 (genetics)
• Male
• Middle Aged
• Myeloproliferative Disorders (classification, diagnosis, genetics, therapy)
• Philadelphia Chromosome
• Societies, Medical
• Uncertainty
• World Health Organization